-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed Announces Private Placement With Expected Gross Proceeds Of ~$10.5M; Will Extend Cash Runway Into Q2 2027

Benzinga·06/10/2026 11:33:19
Listen to the news

Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies

Anticipated pipeline milestones over next six months include obtaining 24-week biomarker and clinical data from Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia and initiation of EXPERTS-ALS Phase 2a trial

Financing includes substantial participation from insiders and leading institutional healthcare investors